Hepta Medical Secures €5.7M to Revolutionize Lung Cancer Treatment
September 5, 2024, 3:34 pm
Hepta Medical, a French innovator in medical devices, has just raised €5.7 million in Series A funding. This financial boost comes from prominent investors like BPI France, M&L Healthcare, and Clery IG. The company is on a mission to change the landscape of lung cancer treatment with its cutting-edge microwave ablation platform.
Founded in 2019, Hepta Medical is a product of the Sofinnova medtech acceleration team and MD Start. Under the leadership of CEO Dr. Thomas Bancel, the company is developing a flexible microwave ablation device designed for minimally invasive procedures. This technology targets early-stage lung cancer, a condition that claims more lives than any other cancer worldwide.
The funds raised will primarily support the 510(k) regulatory approval process in the United States. This step is crucial for initiating clinical trials, a significant milestone for any medical device company. With lung cancer screening programs becoming more prevalent, the need for effective treatments is urgent. Hepta Medical aims to fill this gap with its innovative approach.
The microwave ablation platform is not just another tool in the medical arsenal. It features a proprietary tissue temperature sensor that monitors the ablation zone in real-time. This capability allows clinicians to visualize the treatment area during procedures, enhancing precision and safety. The device is designed to be compatible with existing lung navigation systems, making it versatile and easy to integrate into current medical practices.
What sets Hepta Medical apart is its use of artificial intelligence. The platform incorporates predictive software that combines CT images with temperature data. This integration provides clinicians with a comprehensive view of the ablation zone, enabling informed decisions during procedures. It’s like having a co-pilot in the operating room, guiding the way through complex terrain.
The chairman of the board, Gérard Hascoët, brings valuable experience from Sofinnova Ventures. He will be joined by representatives from BPI France and M&L Healthcare, ensuring a strong governance structure as the company moves forward. Their involvement signals confidence in Hepta Medical’s potential to disrupt the lung cancer treatment landscape.
The urgency of addressing lung cancer cannot be overstated. As the leading cause of cancer-related deaths globally, effective management of early-stage cases is critical. Hepta Medical’s microwave ablation technology offers a controlled, incision-less alternative. This method not only reduces recovery time but also minimizes complications associated with traditional surgical approaches.
The recent funding round is a testament to the growing interest in innovative medical technologies. Investors are increasingly looking for solutions that promise better patient outcomes. Hepta Medical fits this bill perfectly. Its unique approach to thermal ablation therapy positions it at the forefront of lung cancer care.
As the company prepares for clinical trials, it has already achieved significant milestones. In August, Hepta Medical secured its first proprietary patent, completing a trio of patent families under license. This achievement lays a solid foundation for future innovations and strengthens its intellectual property portfolio.
The upcoming CIRSE conference in September will be a pivotal moment for Hepta Medical. The company plans to unveil early preclinical trial results in collaboration with renowned medical centers. This exposure could attract further interest from investors and healthcare professionals alike.
In a world where time is of the essence, Hepta Medical’s technology promises to deliver results quickly and efficiently. The microwave ablation platform is designed to treat patients with minimal disruption to their lives. It’s a breath of fresh air in a field often bogged down by invasive procedures and lengthy recovery times.
The road ahead is filled with challenges, but Hepta Medical is poised to navigate them. With a dedicated team and a clear vision, the company is ready to tackle the complexities of lung cancer treatment. The backing of experienced investors will provide the necessary resources to push boundaries and explore new frontiers.
In conclusion, Hepta Medical’s recent funding marks a significant step in the fight against lung cancer. The innovative microwave ablation platform has the potential to transform patient care. As the company embarks on its clinical trials, the medical community will be watching closely. The hope is that this technology will not only improve outcomes but also offer a new lease on life for countless patients battling this formidable disease.
With each milestone, Hepta Medical is not just advancing technology; it is paving the way for a future where lung cancer treatment is more effective, less invasive, and ultimately, more humane. The journey has just begun, but the destination is clear: a world where lung cancer is no longer a death sentence, but a manageable condition.
Founded in 2019, Hepta Medical is a product of the Sofinnova medtech acceleration team and MD Start. Under the leadership of CEO Dr. Thomas Bancel, the company is developing a flexible microwave ablation device designed for minimally invasive procedures. This technology targets early-stage lung cancer, a condition that claims more lives than any other cancer worldwide.
The funds raised will primarily support the 510(k) regulatory approval process in the United States. This step is crucial for initiating clinical trials, a significant milestone for any medical device company. With lung cancer screening programs becoming more prevalent, the need for effective treatments is urgent. Hepta Medical aims to fill this gap with its innovative approach.
The microwave ablation platform is not just another tool in the medical arsenal. It features a proprietary tissue temperature sensor that monitors the ablation zone in real-time. This capability allows clinicians to visualize the treatment area during procedures, enhancing precision and safety. The device is designed to be compatible with existing lung navigation systems, making it versatile and easy to integrate into current medical practices.
What sets Hepta Medical apart is its use of artificial intelligence. The platform incorporates predictive software that combines CT images with temperature data. This integration provides clinicians with a comprehensive view of the ablation zone, enabling informed decisions during procedures. It’s like having a co-pilot in the operating room, guiding the way through complex terrain.
The chairman of the board, Gérard Hascoët, brings valuable experience from Sofinnova Ventures. He will be joined by representatives from BPI France and M&L Healthcare, ensuring a strong governance structure as the company moves forward. Their involvement signals confidence in Hepta Medical’s potential to disrupt the lung cancer treatment landscape.
The urgency of addressing lung cancer cannot be overstated. As the leading cause of cancer-related deaths globally, effective management of early-stage cases is critical. Hepta Medical’s microwave ablation technology offers a controlled, incision-less alternative. This method not only reduces recovery time but also minimizes complications associated with traditional surgical approaches.
The recent funding round is a testament to the growing interest in innovative medical technologies. Investors are increasingly looking for solutions that promise better patient outcomes. Hepta Medical fits this bill perfectly. Its unique approach to thermal ablation therapy positions it at the forefront of lung cancer care.
As the company prepares for clinical trials, it has already achieved significant milestones. In August, Hepta Medical secured its first proprietary patent, completing a trio of patent families under license. This achievement lays a solid foundation for future innovations and strengthens its intellectual property portfolio.
The upcoming CIRSE conference in September will be a pivotal moment for Hepta Medical. The company plans to unveil early preclinical trial results in collaboration with renowned medical centers. This exposure could attract further interest from investors and healthcare professionals alike.
In a world where time is of the essence, Hepta Medical’s technology promises to deliver results quickly and efficiently. The microwave ablation platform is designed to treat patients with minimal disruption to their lives. It’s a breath of fresh air in a field often bogged down by invasive procedures and lengthy recovery times.
The road ahead is filled with challenges, but Hepta Medical is poised to navigate them. With a dedicated team and a clear vision, the company is ready to tackle the complexities of lung cancer treatment. The backing of experienced investors will provide the necessary resources to push boundaries and explore new frontiers.
In conclusion, Hepta Medical’s recent funding marks a significant step in the fight against lung cancer. The innovative microwave ablation platform has the potential to transform patient care. As the company embarks on its clinical trials, the medical community will be watching closely. The hope is that this technology will not only improve outcomes but also offer a new lease on life for countless patients battling this formidable disease.
With each milestone, Hepta Medical is not just advancing technology; it is paving the way for a future where lung cancer treatment is more effective, less invasive, and ultimately, more humane. The journey has just begun, but the destination is clear: a world where lung cancer is no longer a death sentence, but a manageable condition.